Optimizing Hemodialysis: How Low Dialysate Flow Alters Adequacy and Patient Recovery.

January 17, 2026 updated by: Alexandria University

Low Dialysate Flow: Its Effect on Hemodialysis Adequacy, Dialysis Recovery Time and Patient Reported Outcome Measures.

The goal of this clinical trial is to detect if lower dialysate flow rate can affect hemodialysis adequacy , dialysis recovery time and patients quality of life.

The main questions it aims to answer are:

does low dialysate flow affect hemodialysis adequacy? does green dialysis achievable without affecting hemodialysis adequacy? Researchers will compare hemodialysis session of high dialysate flow to that with low dialysate flow.

Participants will:

underwent hemodialysis for a week with low dialysate flow and another week with high dialysate flow.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Alexandria, Egypt
        • Faculty of Medicine Alexandria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ESKD patients more than or equal 18 years old, on maintenance HD thrice weekly for more than three months and each session lasts for 4 hours.
  • All patients will receive HD via an arterio-venous fistula.
  • All patients will receive HD via the same type of HD machine and the blood pump will be set at 300ml/min.
  • All patients will receive the same type of HD membranes and every effort will be made to achieve the dry weight of the patients.

Exclusion Criteria :

  • Critically ill and hospitalized ESKD patients.
  • Mentally disabled patients.
  • Patients with terminal malignancy or receiving chemotherapy.
  • Patients receiving immune suppression treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ESKD patients
Other: lower dialysate flow rate ( 300ml/min). then testing its effect on hemodialysis adequacy
The aim of this study is to check whether change of dialysate flow from 500ml/min to 300ml/min has a significant impact on dialysis adequacy , dialysis recovery time and patient reported outcome measures in maintenance hemodialysis patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The change of dialysate flow rate, for three successive conventional hemodialysis sessions, from 500ml/min to 300ml/min and its impact on hemodialysis adequacy that is assessed by urea reduction ratio (URR).
Time Frame: Two weeks
Two weeks
The change of dialysate flow rate, for three successive conventional hemodialysis sessions, from 500ml/min to 300ml/min and its impact on hemodialysis adequacy that is assessed by and single-pool Kt/V (spKt/V) using the Daugirdas formula.
Time Frame: Two weeks
Two weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
The effect of lowering dialysate flow rate from 500ml/min (milli per minute) to 300ml/min on dialysis recovery time (DRT) in minutes. Longer duration indicates lower dialysis adequacy.
Time Frame: two weeks
two weeks
The patients reported outcome measures that is assessed by palliative care Outcome Scale - Symptoms Renal (POS S renal). Each symptom takes a score from zero to four (0-4), high score indicates less efficient dialysis.
Time Frame: Tow weeks
Tow weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alexandria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Actual)

August 30, 2025

Study Completion (Actual)

September 30, 2025

Study Registration Dates

First Submitted

December 15, 2025

First Submitted That Met QC Criteria

January 17, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 17, 2026

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0108861

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on End Stage Kidney Disease (ESRD)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe